Recent Updates
Recently added Catalysts

Friedreich Ataxia: 5 biotech companies with clinical-stage programmes

Neurology & PsychiatryOrphan cornerData as of 2026-09-04

Competitors5in the clinic
Median market cap$941Muniverse median $1.20B
Allocated capital$3.2B$8.8B competing
Phase 3 or filed21 mid, 2 early
Pure plays1this indication only
Capital rank64/299crowding rank 35

Friedreich Ataxia sits in the orphan corner of the map: 5 developers, none of them large, with a median market cap of $941M against a $1.20B universe median.

A thin field of small caps usually means a narrow addressable population, so the whole field can be repriced by one readout or one financing.

PTCT carries 68% of the $8.8B competing here, more than the other 4 companies combined.

$3.2B of allocated capital sits in Friedreich Ataxia, 64th of 299 indications, and 1 of the 5 companies are pure plays that trade on this indication alone.

Companies developing drugs for Friedreich Ataxia 5

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
PTCTPTC TherapeuticsVatiquinonePhase 31$6.0BNo3No dated event
LRMRLarimar TherapeuticsNomlabofuspPhase 32$398MYes1 31 Dec 2026
LXEOLexeo TherapeuticsLow dose LX2006Phase 23$397MNo3 31 Dec 2026
SLDBSolid BiosciencesSGT-212Phase 11$1.1BNo2 31 Dec 2026
DSGNDesign TherapeuticsDT-216P2Phase 12$941MNo6 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. PTCT holds 68% of the $8.8B competing in this indication.

Why Friedreich Ataxia is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Friedreich Ataxia has 5 competitors and a median of $941M.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

SCN2A Encephalopathy1 company · $3.3B · median $9.9BUncontestedTonic-Clonic Epilepsy1 company · $3.3B · median $9.9BUncontestedADHD2 companies · $3.4B · median $6.7BConcentrated betAlzheimer's Disease5 companies · $2.9B · median $397MOrphan cornerChronic Inflammatory Demyelinating Polyneuropathy2 companies · $3.6B · median $7.0BConcentrated betExcessive Daytime Somnolence1 company · $2.7B · median $10.9BUncontestedSmoking Cessation1 company · $2.7B · median $10.9BUncontestedSpinal Muscular Atrophy Type III2 companies · $3.7B · median $4.6BConcentrated bet

Friedreich Ataxia pipeline questions

Which biotech companies are developing drugs for Friedreich Ataxia?

PTC Therapeutics (PTCT, Vatiquinone, Phase 3); Larimar Therapeutics (LRMR, Nomlabofusp, Phase 3); Lexeo Therapeutics (LXEO, Low dose LX2006, Phase 2); Solid Biosciences (SLDB, SGT-212, Phase 1); Design Therapeutics (DSGN, DT-216P2, Phase 1). Those are the 5 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Friedreich Ataxia.

How advanced is the Friedreich Ataxia pipeline?

Of the 5 clinical-stage programmes in Friedreich Ataxia, 2 are in Phase 3 or filed, 1 is in mid-stage development and 2 are in early-stage development.

Which company leads the Friedreich Ataxia field?

PTCT is the largest developer in Friedreich Ataxia, holding 68% of the $8.8B of market capitalisation competing in the indication. The median competitor is worth $941M.

When is the next Friedreich Ataxia catalyst?

The next dated catalyst in Friedreich Ataxia is LRMR on 31 Dec 2026. 4 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map